Alternative commercialisation models offer lifeline to future of gene therapies
Nonprofit founder and CEO, Craig Martin, notes that the industry will likely see more alternative gene therapy commercialisation models in the future.
Cytiva Navigating cell therapy WP 4
Cell and gene therapy investment strategy pivots as funding dries up
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
Regeneron and Tessera join forces to forge in vivo AATD gene therapy
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
IASO Bio gains Hong Kong approval for Fucaso application
UK-developed leukaemia cell therapy to be offered on NHS
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
